AI Engines For more Details: Perplexity Kagi Labs You
Type 2 Diabetes Mellitus: Rosiglitazone hydrochloride belongs to a class of medications called thiazolidinediones (TZDs) or glitazones. It helps control blood sugar levels in patients with type 2 diabetes by improving insulin sensitivity in peripheral tissues such as muscle and fat, leading to increased glucose uptake and utilization. It may be prescribed alone or in combination with other antidiabetic drugs to achieve glycemic control.
Insulin Resistance: Insulin resistance is a condition in which the body's cells become less responsive to the effects of insulin, leading to impaired glucose uptake and elevated blood sugar levels. Rosiglitazone hydrochloride helps mitigate insulin resistance by activating peroxisome proliferator-activated receptor gamma (PPAR-Ξ³) receptors, which regulate genes involved in glucose and lipid metabolism.
Hyperglycemia: Hyperglycemia, or high blood sugar, is a hallmark feature of diabetes mellitus. Rosiglitazone hydrochloride helps lower blood glucose levels by increasing insulin sensitivity and decreasing hepatic glucose production. By improving glycemic control, it reduces the risk of diabetes-related complications such as neuropathy, nephropathy, and retinopathy.
Metabolic Syndrome: Rosiglitazone hydrochloride may be beneficial in patients with metabolic syndrome, a cluster of conditions including obesity, insulin resistance, dyslipidemia, and hypertension, which collectively increase the risk of cardiovascular disease and type 2 diabetes. By addressing insulin resistance and improving lipid profiles, rosiglitazone hydrochloride can help mitigate some components of metabolic syndrome.
Polycystic Ovary Syndrome (PCOS): PCOS is a common endocrine disorder characterized by hormonal imbalances, insulin resistance, and irregular menstrual cycles. Rosiglitazone hydrochloride may be used off-label in some cases to improve insulin sensitivity, regulate menstrual cycles, and reduce androgen levels in women with PCOS.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 2.2 | 0.3 | 6.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.9 | |
| Allergies | 1.6 | 1 | 0.6 |
| Allergy to milk products | 0.5 | 0.7 | -0.4 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 3.3 | 2.9 | 0.14 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.6 | |
| Ankylosing spondylitis | 1 | 0.6 | 0.67 |
| Anorexia Nervosa | 0.4 | 1.9 | -3.75 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.3 | 0.67 |
| Asthma | 2.7 | 1.5 | 0.8 |
| Atherosclerosis | 1.1 | 1.4 | -0.27 |
| Atrial fibrillation | 1.8 | 1.5 | 0.2 |
| Autism | 4.4 | 3.9 | 0.13 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 1.3 | 0.8 | 0.63 |
| Brain Trauma | 0.8 | -0.8 | |
| Breast Cancer | 0.6 | 0.6 | |
| Cancer (General) | 0.3 | 0.6 | -1 |
| Carcinoma | 2.4 | 0.7 | 2.43 |
| Celiac Disease | 1.9 | 1 | 0.9 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 2.4 | 2.7 | -0.13 |
| Chronic Kidney Disease | 1 | 0.9 | 0.11 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 0.8 | 0.25 |
| Chronic Urticaria (Hives) | 1 | -1 | |
| Coagulation / Micro clot triggering bacteria | 0.9 | 0.5 | 0.8 |
| Cognitive Function | 1.3 | 0.5 | 1.6 |
| Colorectal Cancer | 3.6 | 1.6 | 1.25 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 0.3 | 1.4 | -3.67 |
| COVID-19 | 4.4 | 4.4 | 0 |
| Crohn's Disease | 4.9 | 2.2 | 1.23 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 2.2 | 0.8 | 1.75 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 5.7 | 3.3 | 0.73 |
| Eczema | 0.3 | 0.8 | -1.67 |
| Endometriosis | 0.7 | 0.5 | 0.4 |
| Eosinophilic Esophagitis | 0.5 | 0.5 | |
| Epilepsy | 1.4 | 1.3 | 0.08 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 1.9 | 1.5 | 0.27 |
| Functional constipation / chronic idiopathic constipation | 2.1 | 2.3 | -0.1 |
| gallstone disease (gsd) | 1 | 0.8 | 0.25 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.3 | 2.3 | |
| Generalized anxiety disorder | 0.9 | 0.8 | 0.13 |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.9 | 0.8 | 0.13 |
| Gulf War Syndrome | 0.8 | -0.8 | |
| Halitosis | 1.4 | 0.2 | 6 |
| Hashimoto's thyroiditis | 1.7 | 0.6 | 1.83 |
| Heart Failure | 1.3 | 0.6 | 1.17 |
| hemorrhagic stroke | 0.7 | 0.7 | |
| Hidradenitis Suppurativa | 0.9 | 0.9 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hypercholesterolemia (High Cholesterol) | 0.2 | -0.2 | |
| hyperglycemia | 0.7 | -0.7 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.3 | 2.2 | -0.69 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.7 | 0.4 | 0.75 |
| IgA nephropathy (IgAN) | 1.5 | 1.8 | -0.2 |
| Inflammatory Bowel Disease | 3.8 | 3.9 | -0.03 |
| Insomnia | 0.3 | 1.1 | -2.67 |
| Intelligence | 0.9 | 0.9 | 0 |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 2.2 | 2.5 | -0.14 |
| ischemic stroke | 0.7 | 1.1 | -0.57 |
| Liver Cirrhosis | 3.2 | 1.6 | 1 |
| Long COVID | 3.1 | 2.4 | 0.29 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.3 | 0.3 | |
| Mast Cell Issues / mastitis | 0.6 | 0.6 | |
| ME/CFS with IBS | 0.5 | 0.3 | 0.67 |
| ME/CFS without IBS | 0.6 | 0.5 | 0.2 |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 3.4 | 3.8 | -0.12 |
| Mood Disorders | 4.9 | 3.3 | 0.48 |
| Multiple Sclerosis | 2.4 | 2.8 | -0.17 |
| myasthenia gravis | 0.8 | -0.8 | |
| neuropathic pain | 0.3 | 1.3 | -3.33 |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.6 | 0.9 | 0.78 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 2.5 | 3.6 | -0.44 |
| obsessive-compulsive disorder | 2.5 | 1 | 1.5 |
| Osteoarthritis | 0.9 | 0.3 | 2 |
| Osteoporosis | 1.1 | 0.3 | 2.67 |
| pancreatic cancer | 0.6 | 0.6 | |
| Parkinson's Disease | 2.4 | 2.7 | -0.13 |
| Polycystic ovary syndrome | 3.5 | 1.1 | 2.18 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.9 | -0.9 | |
| Primary sclerosing cholangitis | 1.2 | 0.7 | 0.71 |
| Psoriasis | 0.6 | 2 | -2.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.9 | 2 | 0.45 |
| Rosacea | 0.8 | -0.8 | |
| Schizophrenia | 2.2 | 1.5 | 0.47 |
| scoliosis | 0.3 | -0.3 | |
| sensorineural hearing loss | 0.5 | 0.5 | |
| Sjögren syndrome | 0.9 | 1.6 | -0.78 |
| Sleep Apnea | 0.3 | 1.1 | -2.67 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 1.6 | 1.6 | 0 |
| Systemic Lupus Erythematosus | 2.1 | 0.5 | 3.2 |
| Tic Disorder | 0.6 | 0.4 | 0.5 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.7 | 1.7 | 0 |
| Type 2 Diabetes | 4.3 | 3.8 | 0.13 |
| Ulcerative colitis | 2.7 | 4 | -0.48 |
| Unhealthy Ageing | 3.4 | 1 | 2.4 |
| Vitiligo | 1.3 | 0.4 | 2.25 |
